Genovis Q2 2024: Focusing fully on the enzyme business - Redeye

Redeye updates its view on Genovis following the Q2 report and the announced divestment of its antibody business. As a consequence, we have revised our model to reflect lower sales projections and adjusted our fair value range accordingly. However, we believe the 21% decline on the report day was an overreaction and with the share trading in bear case territory R/R looks attractive.

Länk till analysen i sin helhet: https://www.redeye.se/research/1031568/genovis-q2-2024-focusing-fully-on-the-enzyme-business?utm_source=finwire&utm_medium=RSS